N.A. Semashko National Research Institute of Public Health, a federal state budgetary institution, and MSD, an international pharmaceutical company, announced that they begin to collaborate under the agreement on the research for the purposes of health care.
The agreement provides for the studies of impact made by the innovative health care technology on socio-economic indicators of the Russian Federation and its subjects, analysis of priorities in the health care system and identification of factors ensuring the availability of innovative solutions.
Ramil Khabriev, the Director of N.A. Semashko National Research Institute of Public Health, academician of RAS, Doctor of Medical Sciences, Doctor of Pharmaceutical Sciences, professor, said, “The project has a chance to become a successful example of public-private partnership aimed at improving the public health in Russia.”
Marwan Akar, MSD Director General in Russia, Kazakhstan and Belarus, said, “We are encouraged by the collaboration with N.A. Semashko Institute, one of the leading institutions in the area of public health. The implementation of the joint project will bring together leading Russian and international practices in health care and will become a platform for developing the evidence base required for the Russian health care system.”
The collaboration will be supported by the Center for Expertise and Innovation in Health Care of MSD established in 2016.